This trial will test the safety and tolerability of the drug MK-6194 in people with moderate to severe atopic dermatitis who haven't responded to other treatments.
2 Primary · 8 Secondary · Reporting Duration: Days 15, 29, 43, and 85: Predose
Experimental Treatment
72 Total Participants · 6 Treatment Groups
Primary Treatment: MK-6194 · Has Placebo Group · Phase 1
Age 18 - 75 · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: